Search Results

Medicure Inc. announces it has signed an asset purchase agreement with CanAm Bioresearch Inc. for the acquisition of the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF) announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2024.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2023.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2023.

Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time.